Velosity has acquired Elucid, a Boston-based AI medical technology company, for an undisclosed amount. This purchase brings Elucid's advanced AI platform, focused on cardiovascular disease diagnostics, under Velosity's ownership. Elucid specializes in developing AI to identify invisible features of risk, aiming to provide physicians with a more precise view of atherosclerosis, the primary cause of cardiovascular disease, for CCTA-guided personalized care.
Elucid's core offering includes its FDA-cleared Plaque-IQ™ image analysis software. This technology is designed to assist physicians in prioritizing and personalizing treatment by offering critical information regarding the type and amount of plaque in arteries, which can lead to heart attack and stroke. Furthermore, Elucid is actively pursuing an indication for FFR-CT, derived from its plaque algorithm. This capability aims to help physicians non-invasively identify coronary blockages and assess the extent of a patient’s ischemia, demonstrating concordance between plaque and FFR-CT.
The acquisition of Elucid by Velosity represents a strategic move to integrate cutting-edge AI capabilities into cardiovascular diagnostics. This transaction is anticipated to enhance Velosity's offerings in medical technology, leveraging Elucid's expertise in advanced image analysis and risk assessment. The combination of Velosity's resources with Elucid's innovative platform is poised to accelerate the development and broader adoption of personalized care solutions for heart disease.
The combined entity is positioned to advance the standard of care in cardiovascular health. By integrating Elucid's precise diagnostic tools, the aim is to empower physicians with more comprehensive data, leading to earlier and more targeted interventions for patients at risk of heart attack and stroke. This integration is set to drive innovation in non-invasive diagnostics and personalized treatment strategies.